Fig. 1.

Elevated METTL1 expression correlates with poor prognosis of patients with CRPC. A Heat map of transcriptome sequencing indicates differentially expressed genes between HSPC and CRPC patient tissues. The screening thresholds:|Fold change|>2 and p-value < 0.05. B Differential expression of METTL1 between HSPC and CRPC tissue via transcriptome sequencing. C-D RT-qPCR and western blot were performed to detect the mRNA and protein level of METTL1 between HSPC and CRPC patients’ samples. E Immunohistochemistry (IHC) assay was carried out to determine the METTL1 expression on a tissue microarray (TMA). Objective magnification: 40X, 100X, and 200X. F-G Immunohistochemical staining scores of METTL1 for each HSPC and CRPC patient in tissue microarrays (F) and the proportion of patients with different levels of METTL1 staining (G). H-I Disease-free survival of patients in SU2C database and TMA using Kaplan–Meier survival analysis. **P < 0.01; ****P < 0.0001